Global Recombinant Hirudin Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Hirudin Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Hirudin is the most potent natural inhibitor of thrombin. Unlike antithrombin, hirudin binds to and inhibits only the activity of thrombin, with a specific activity on fibrinogen. Therefore, hirudin prevents or dissolves the formation of clots and thrombi (i.e., it has a thrombolytic activity), and has therapeutic value in blood coagulation disorders, in the treatment of skin hematomas and of superficial varicose veins, either as an injectable or a topical application cream. In some aspects, hirudin has advantages over more commonly used anticoagulants and thrombolytics, such as heparin, as it does not interfere with the biological activity of other serum proteins, and can also act on complexed thrombin.
It is difficult to extract large amounts of hirudin from natural sources, so a method for producing and purifying this protein using recombinant biotechnology has been developed. This has led to the development and marketing of a number of hirudin-based anticoagulant pharmaceutical products. Several other direct thrombin inhibitors are derived chemically from hirudin.
Recombinant Hirudin is derived from yeast and the polypeptide chain contains 65 amino acids and its Mw is 6979.5 Dalton which is identical to natural Hirudin except for the substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. The Recombinant Hirudin is purified by proprietary chromatographic techniques.
Recombinant Hirudin report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Hirudin market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Thrombosis Disease and Tumor Disease are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Hirudin industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Recombinant Hirudin key manufacturers include Abbott, The Medicines Company, Teva Pharmaceutical, Pfizer, Pentapharm, PrimeGene, Aniara Diagnostica, Bioassay Technology Laboratory and Novus Biologicals, etc. Abbott, The Medicines Company, Teva Pharmaceutical are top 3 players and held % sales share in total in 2022.
Recombinant Hirudin can be divided into 12000ATU/mg and 16000ATU/mg, etc. 12000ATU/mg is the mainstream product in the market, accounting for % sales share globally in 2022.
Recombinant Hirudin is widely used in various fields, such as Thrombosis Disease and Tumor Disease, etc. Thrombosis Disease provides greatest supports to the Recombinant Hirudin industry development. In 2022, global % sales of Recombinant Hirudin went into Thrombosis Disease filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Hirudin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Abbott
The Medicines Company
Teva Pharmaceutical
Pfizer
Pentapharm
PrimeGene
Aniara Diagnostica
Bioassay Technology Laboratory
Novus Biologicals
Merck KGaA
Segment by Type
12000ATU/mg
16000ATU/mg
Thrombosis Disease
Tumor Disease
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Recombinant Hirudin market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Hirudin, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Hirudin industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Hirudin in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Hirudin introduction, etc. Recombinant Hirudin Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Recombinant Hirudin market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
It is difficult to extract large amounts of hirudin from natural sources, so a method for producing and purifying this protein using recombinant biotechnology has been developed. This has led to the development and marketing of a number of hirudin-based anticoagulant pharmaceutical products. Several other direct thrombin inhibitors are derived chemically from hirudin.
Recombinant Hirudin is derived from yeast and the polypeptide chain contains 65 amino acids and its Mw is 6979.5 Dalton which is identical to natural Hirudin except for the substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. The Recombinant Hirudin is purified by proprietary chromatographic techniques.
Recombinant Hirudin report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Hirudin market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Thrombosis Disease and Tumor Disease are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Hirudin industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Recombinant Hirudin key manufacturers include Abbott, The Medicines Company, Teva Pharmaceutical, Pfizer, Pentapharm, PrimeGene, Aniara Diagnostica, Bioassay Technology Laboratory and Novus Biologicals, etc. Abbott, The Medicines Company, Teva Pharmaceutical are top 3 players and held % sales share in total in 2022.
Recombinant Hirudin can be divided into 12000ATU/mg and 16000ATU/mg, etc. 12000ATU/mg is the mainstream product in the market, accounting for % sales share globally in 2022.
Recombinant Hirudin is widely used in various fields, such as Thrombosis Disease and Tumor Disease, etc. Thrombosis Disease provides greatest supports to the Recombinant Hirudin industry development. In 2022, global % sales of Recombinant Hirudin went into Thrombosis Disease filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Hirudin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Abbott
The Medicines Company
Teva Pharmaceutical
Pfizer
Pentapharm
PrimeGene
Aniara Diagnostica
Bioassay Technology Laboratory
Novus Biologicals
Merck KGaA
Segment by Type
12000ATU/mg
16000ATU/mg
Segment by Application
Thrombosis Disease
Tumor Disease
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Recombinant Hirudin market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Hirudin, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Hirudin industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Hirudin in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Hirudin introduction, etc. Recombinant Hirudin Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Recombinant Hirudin market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices